Supplementary appendix

Size: px
Start display at page:

Download "Supplementary appendix"

Transcription

1 Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health 2018; published online April 24.

2 Report Run Date: 06-Dec-2017 Data Lock Date: 15-Nov :00:05 Earliest Reaction Date: 27-Jan-2015 MedDRA Version: MedDRA 20.1 Bexsero PAP: Bexsero Product Analysis Print (PAP) of all cases received between 01/09/2017 and 31/05/2017 in patients aged under 18 months. Report Run Date: 06-Dec-2017, Page 1

3 Cardiac disorders Cardiac signs and symptoms NEC Cyanosis 9 0 Palpitations 2 0 Rate and rhythm disorders NEC Bradycardia 6 0 Bradycardia neonatal 3 0 Tachycardia 11 0 Supraventricular arrhythmias Supraventricular tachycardia 1 0 Ventricular arrhythmias and cardiac arrest Cardiac arrest 2 0 Cardio-respiratory arrest 1 0 Cardiac disorders SOC TOTAL 35 0 Report Run Date: 06-Dec-2017, Page 2

4 Ear disorders Tympanic membrane disorders (excl infections) Tympanic membrane hyperaemia 1 0 Ear disorders SOC TOTAL 1 0 Report Run Date: 06-Dec-2017, Page 3

5 Eye disorders Lacrimation disorders Lacrimation increased 1 0 Lid, lash and lacrimal infections, irritations and inflammations Eyelid oedema 1 0 Ocular disorders NEC Eye disorder 1 0 Eye swelling 1 0 Ocular infections, inflammations and associated manifestations Ocular hyperaemia 1 0 Ocular nerve and muscle disorders Eye movement disorder 5 0 Strabismus 2 0 Ocular sensation disorders Photophobia 1 0 Pupil disorders Mydriasis 1 0 Pupils unequal 1 0 Scleral structural change, deposit and degeneration Scleral discolouration 1 0 Visual disorders NEC Vision blurred 1 0 Eye disorders SOC TOTAL 17 0 Report Run Date: 06-Dec-2017, Page 4

6 Gastrointestinal disorders Abdominal findings abnormal Gastrointestinal sounds abnormal 1 0 Diarrhoea (excl infective) Diarrhoea 44 0 Faecal abnormalities NEC Abnormal faeces 2 0 Faeces discoloured 3 0 Faeces soft 1 0 Mucous stools 3 0 Flatulence, bloating and distension Abdominal distension 3 0 Flatulence 3 0 Gastritis (excl infective) Reflux gastritis 1 0 Gastrointestinal and abdominal pains (excl oral and throat) Abdominal pain 4 0 Abdominal pain upper 4 0 Gastrointestinal atonic and hypomotility disorders NEC Constipation 4 0 Gastrooesophageal reflux disease 1 0 Gastrointestinal dyskinetic disorders Change of bowel habit 1 0 Gastrointestinal signs and symptoms NEC Abdominal discomfort 7 0 Dysphagia 1 0 Gastrointestinal stenosis and obstruction NEC Intussusception 1 0 Nausea and vomiting symptoms Infantile vomiting 6 0 Retching 1 0 Vomiting 61 0 Vomiting projectile 5 0 Non-site specific gastrointestinal haemorrhages Haematochezia 1 0 Oral soft tissue pain and paraesthesia Oral pain 1 0 Oral soft tissue signs and symptoms Oral mucosal blistering 1 0 Oral soft tissue swelling and oedema Lip swelling 2 0 Stomatitis and ulceration Mouth ulceration 1 0 Tongue signs and symptoms Swollen tongue 3 0 Gastrointestinal disorders SOC TOTAL Report Run Date: 06-Dec-2017, Page 5

7 General disorders Administration site reactions NEC Administration site erythema 1 0 Asthenic conditions Asthenia 3 0 Fatigue 4 0 Malaise 45 0 Body temperature altered Hypothermia 1 0 Death and sudden death Death 3 3 Sudden death 1 1 Sudden infant death syndrome 1 1 Febrile disorders Fever neonatal 1 0 Hyperpyrexia 3 0 Pyrexia Feelings and sensations NEC Chills 8 0 Feeling abnormal 8 0 Feeling cold 2 0 Feeling hot 6 0 Feeling jittery 1 0 Gait disturbances Gait disturbance 8 0 Gait inability 3 0 Loss of control of legs 1 0 General signs and symptoms NEC Condition aggravated 3 0 Crying 95 0 Developmental delay 1 0 General physical health deterioration 2 0 Glassy eyes 2 0 Induration 9 0 Irritability postvaccinal 4 0 Local reaction 7 0 Moaning 3 0 Peripheral swelling 24 0 Secretion discharge 1 0 Swelling 20 0 Inflammations Inflammation 6 0 Injection site reactions Injected limb mobility decreased 1 0 Injection site bruising 2 0 Injection site discolouration 1 0 Injection site discomfort 1 0 Injection site erythema 13 0 Injection site haemorrhage 1 0 Injection site induration 2 0 Injection site inflammation 2 0 Injection site joint erythema 1 0 Injection site joint inflammation 1 0 Injection site mass 43 0 Report Run Date: 06-Dec-2017, Page 6

8 General disorders General disorders cont'd Injection site nodule 1 0 Injection site oedema 1 0 Injection site pain 3 0 Injection site pruritus 1 0 Injection site rash 1 0 Injection site swelling 10 0 Injection site vesicles 3 0 Injection site warmth 3 0 Mass conditions NEC Mass 11 0 Pain and discomfort NEC Discomfort 3 0 Pain 21 0 Tenderness 1 0 Vaccination site reactions Extensive swelling of vaccinated limb 2 0 Vaccination site bruising 8 0 Vaccination site cyst 1 0 Vaccination site discharge 3 0 Vaccination site discolouration 9 0 Vaccination site discomfort 2 0 Vaccination site eczema 1 0 Vaccination site erythema 55 0 Vaccination site haematoma 2 0 Vaccination site induration 34 0 Vaccination site inflammation 7 0 Vaccination site irritation 1 0 Vaccination site joint movement impairment 1 0 Vaccination site mass 54 0 Vaccination site movement impairment 1 0 Vaccination site nodule 5 0 Vaccination site oedema 1 0 Vaccination site pain 17 0 Vaccination site pallor 1 0 Vaccination site rash 11 0 Vaccination site reaction 6 0 Vaccination site scar 6 0 Vaccination site swelling 56 0 Vaccination site warmth 10 0 General disorders SOC TOTAL Report Run Date: 06-Dec-2017, Page 7

9 Immune system disorders Allergic conditions NEC Hypersensitivity 8 0 Multiple allergies 2 0 Allergies to foods, food additives, drugs and other chemicals Allergy to vaccine 1 0 Anaphylactic and anaphylactoid responses Anaphylactic reaction 4 0 Immune system disorders SOC TOTAL 15 0 Report Run Date: 06-Dec-2017, Page 8

10 Infections Abdominal and gastrointestinal infections Gastroenteritis 1 0 Bacterial infections NEC Arthritis bacterial 2 0 Bacterial infection 1 0 Cellulitis 9 0 Meningitis bacterial 1 0 Skin bacterial infection 1 0 Vaccination site cellulitis 7 0 Bone and joint infections Osteomyelitis 1 0 Central nervous system and spinal infections Encephalitis 1 0 Meningitis 2 0 Meningitis aseptic 3 0 Ear infections Ear infection 1 0 Otitis externa 1 0 Eye and eyelid infections Conjunctivitis 1 0 Infections NEC Abscess 3 0 Infection 1 0 Lymph gland infection 1 0 Vaccination site abscess 1 0 Vaccination site infection 3 0 Lower respiratory tract and lung infections Lower respiratory tract infection 2 0 Lung infection 1 0 Sepsis, bacteraemia, viraemia and fungaemia NEC Sepsis 10 0 Sepsis neonatal 1 0 Skin structures and soft tissue infections Skin infection 1 0 Subcutaneous abscess 1 0 Staphylococcal infections Furuncle 1 0 Streptococcal infections Scarlet fever 1 0 Tuberculous infections Erythema induratum 1 0 Upper respiratory tract infections Croup infectious 2 0 Nasopharyngitis 3 0 Tonsillitis 1 0 Viral infections NEC Bronchiolitis 2 0 Gastroenteritis viral 2 0 Viral infection 1 0 Viral rash 1 0 Viral upper respiratory tract infection 1 0 Infections SOC TOTAL 73 0 Report Run Date: 06-Dec-2017, Page 9

11 Injuries Medication errors, product use errors and issues NEC Inadequate aseptic technique in use of product 1 0 Non-site specific procedural complications Post procedural swelling 1 0 Product administration errors and issues Drug administered at inappropriate site 1 0 Drug administered to patient of inappropriate age 1 0 Drug administration error 1 0 Inappropriate schedule of drug administration 1 0 Incorrect route of drug administration 1 0 Skin injuries NEC Contusion 7 0 Laceration 1 0 Injuries SOC TOTAL 15 0 Report Run Date: 06-Dec-2017, Page 10

12 Investigations Blood gas and acid base analyses Oxygen saturation decreased 6 0 Cerebrospinal fluid tests (excl microbiology) CSF white blood cell count increased 1 0 Chemistry analyses NEC Inflammatory marker increased 2 0 Heart rate and pulse investigations Heart rate abnormal 1 0 Heart rate increased 7 0 Physical examination procedures and organ system status Body temperature abnormal 5 0 Body temperature decreased 3 0 Body temperature fluctuation 1 0 Body temperature increased 30 0 Respiratory rate increased 8 0 Protein analyses NEC C-reactive protein increased 10 0 Respiratory tract and thoracic imaging procedures Chest X-ray abnormal 1 0 Vascular tests NEC (incl blood pressure) Capillary nail refill test abnormal 1 0 White blood cell analyses White blood cell count increased 4 0 Investigations SOC TOTAL 80 0 Report Run Date: 06-Dec-2017, Page 11

13 Metabolic disorders Appetite disorders Decreased appetite 18 0 Hypophagia 4 0 General nutritional disorders NEC Food aversion 1 0 Poor feeding infant 41 0 Hypoglycaemic conditions NEC Hypoglycaemia 1 0 Metabolic acidoses (excl diabetic acidoses) Metabolic acidosis 1 0 Potassium imbalance Hyperkalaemia 1 0 Sodium imbalance Hyponatraemia 1 0 Total fluid volume decreased Dehydration 2 0 Metabolic disorders SOC TOTAL 70 0 Report Run Date: 06-Dec-2017, Page 12

14 Muscle & tissue disorders Joint related signs and symptoms Arthralgia 2 0 Muscle pains Myalgia 2 0 Muscle related signs and symptoms NEC Muscle spasms 1 0 Muscle twitching 5 0 Muscle tone abnormalities Floppy infant 15 0 Muscle rigidity 3 0 Muscle weakness conditions Muscular weakness 2 0 Musculoskeletal and connective tissue pain and discomfort Limb discomfort 1 0 Musculoskeletal discomfort 1 0 Pain in extremity 9 0 Musculoskeletal and connective tissue signs and symptoms NEC Limb mass 3 0 Musculoskeletal stiffness 6 0 Posture abnormal 1 0 Weight bearing difficulty 5 0 Muscle & tissue disorders SOC TOTAL 56 0 Report Run Date: 06-Dec-2017, Page 13

15 Nervous system disorders Abnormal reflexes Kernig's sign 1 0 Absence seizures Petit mal epilepsy 2 0 Coordination and balance disturbances Balance disorder 2 0 Dysstasia 2 0 Disturbances in consciousness NEC Depressed level of consciousness 2 0 Lethargy 19 0 Loss of consciousness 3 0 Somnolence 23 0 Syncope 1 0 Dyskinesias and movement disorders NEC Dyskinesia 6 0 Hypokinesia 1 0 Movement disorder 1 0 Generalised tonic-clonic seizures Generalised tonic-clonic seizure 9 0 Headaches NEC Headache 2 0 Mental impairment (excl dementia and memory loss) Disturbance in attention 1 0 Muscle tone abnormal Hypertonia 2 0 Hypotonia 21 0 Narcolepsy and hypersomnia Hypersomnia 3 0 Neurological signs and symptoms NEC Decerebrate posture 1 0 Drooling 1 0 Exaggerated startle response 1 0 Fontanelle bulging 3 0 Hyporesponsive to stimuli 2 0 Meningism 2 0 Presyncope 3 0 Unresponsive to stimuli 24 0 Neuromuscular disorders NEC Hypotonic-hyporesponsive episode 2 0 Paraesthesias and dysaesthesias Hyperaesthesia 1 0 Seizures and seizure disorders NEC Epilepsy 1 0 Febrile convulsion 26 0 Partial seizures 3 0 Seizure 17 0 Seizure anoxic 1 0 Seizure like phenomena 1 0 Status epilepticus 1 0 Tonic clonic movements 1 0 Sleep disturbances NEC Poor quality sleep 1 0 Speech and language abnormalities Report Run Date: 06-Dec-2017, Page 14

16 Nervous system disorders Nervous system disorders cont'd Speech disorder developmental 1 0 Tremor (excl congenital) Tremor 9 0 Nervous system disorders SOC TOTAL Report Run Date: 06-Dec-2017, Page 15

17 Pregnancy conditions Neonatal metabolic and endocrine disorders Hypothermia neonatal 1 0 Pregnancy conditions SOC TOTAL 1 0 Report Run Date: 06-Dec-2017, Page 16

18 Psychiatric disorders Abnormal behaviour NEC Abnormal behaviour 8 0 Breath holding 2 0 Staring 3 0 Anxiety disorders NEC Separation anxiety disorder 1 0 Anxiety symptoms Agitation 8 0 Agitation neonatal 1 0 Anxiety 1 0 Stress 1 0 Behaviour and socialisation disturbances Personality change 1 0 Social avoidant behaviour 2 0 Decreased physical activity levels Catatonia 1 0 Disturbances in initiating and maintaining sleep Insomnia 8 0 Emotional and mood disturbances NEC Emotional distress 11 0 Irritability 80 0 Mood altered 2 0 Increased physical activity levels Restlessness 20 0 Mood alterations with depressive symptoms Decreased interest 1 0 Depressed mood 1 0 Mood disorders NEC Listless 5 0 Parasomnias Sleep terror 3 0 Sleep disorders NEC Sleep disorder 7 0 Somatic symptom disorders Conversion disorder 1 0 Speech articulation and rhythm disturbances Screaming 28 0 Psychiatric disorders SOC TOTAL Report Run Date: 06-Dec-2017, Page 17

19 Renal & urinary disorders Bladder and urethral symptoms Dysuria 1 0 Renal structural abnormalities and trauma Kidney enlargement 1 0 Renal & urinary disorders SOC TOTAL 2 0 Report Run Date: 06-Dec-2017, Page 18

20 Respiratory disorders Breathing abnormalities Apnoea 14 0 Apnoeic attack 2 0 Dyspnoea 15 0 Grunting 3 0 Hypopnoea 7 0 Hypoventilation 1 0 Irregular breathing 1 0 Respiratory arrest 8 0 Respiratory depression 1 0 Respiratory distress 1 0 Tachypnoea 6 0 Bronchospasm and obstruction Wheezing 3 0 Conditions associated with abnormal gas exchange Respiratory acidosis 1 0 Coughing and associated symptoms Cough 6 0 Laryngeal spasm, oedema and obstruction Stridor 1 0 Lower respiratory tract signs and symptoms Rales 1 0 Nasal congestion and inflammations Nasal congestion 1 0 Neonatal hypoxic conditions Infantile apnoea 4 0 Neonatal hypoxia 4 0 Pharyngeal disorders (excl infections and neoplasms) Pharyngeal erythema 1 0 Respiratory failures (excl neonatal) Acute respiratory failure 1 0 Respiratory tract disorders NEC Respiratory disorder 4 0 Upper respiratory tract signs and symptoms Choking 2 0 Increased viscosity of upper respiratory secretion 1 0 Nasal obstruction 1 0 Oropharyngeal blistering 1 0 Oropharyngeal pain 1 0 Rhinorrhoea 7 0 Respiratory disorders SOC TOTAL 99 0 Report Run Date: 06-Dec-2017, Page 19

21 Skin disorders Angioedemas Angioedema 1 0 Swelling face 3 0 Apocrine and eccrine gland disorders Cold sweat 6 0 Hyperhidrosis 1 0 Bullous conditions Blister 4 0 Erythema multiforme 1 0 Dermal and epidermal conditions NEC Dry skin 1 0 Pain of skin 2 0 Papule 2 0 Skin burning sensation 1 0 Skin discolouration 24 0 Skin induration 3 0 Skin lesion 1 0 Skin reaction 6 0 Skin tightness 1 0 Skin warm 14 0 Dermatitis and eczema Dermatitis allergic 2 0 Dermatitis atopic 1 0 Dermatitis diaper 1 0 Eczema 2 0 Erythemas Erythema 58 0 Generalised erythema 1 0 Exfoliative conditions Skin exfoliation 1 0 Pruritus NEC Pruritus 5 0 Purpura and related conditions Henoch-Schonlein purpura 2 0 Petechiae 14 0 Purpura 4 0 Rashes, eruptions and exanthems NEC Rash 54 0 Rash erythematous 6 0 Rash generalised 11 0 Rash macular 18 0 Rash maculo-papular 3 0 Rash papular 6 0 Rash vesicular 1 0 Skin and subcutaneous conditions NEC Skin mass 3 0 Skin cysts and polyps Dermal cyst 1 0 Skin dystrophies Skin wrinkling 4 0 Skin vasomotor conditions Livedo reticularis 9 0 Urticarias Report Run Date: 06-Dec-2017, Page 20

22 Skin disorders Skin disorders cont'd Urticaria 19 0 Skin disorders SOC TOTAL Report Run Date: 06-Dec-2017, Page 21

23 Social circumstances Disability issues Immobile 1 0 Social circumstances SOC TOTAL 1 0 Report Run Date: 06-Dec-2017, Page 22

24 Vascular disorders Arterial inflammations Kawasaki's disease 3 0 Circulatory collapse and shock Circulatory collapse 4 0 Peripheral circulatory failure 1 0 Shock 3 0 Haemorrhages NEC Haematoma 1 0 Lymphoedemas Lymphoedema 1 0 Peripheral vascular disorders NEC Flushing 3 0 Peripheral vasoconstriction, necrosis and vascular insufficiency Peripheral coldness 6 0 Site specific vascular disorders NEC Pallor 53 0 Vascular disorders SOC TOTAL 75 0 TOTAL REACTIONS FOR DRUG TOTAL REPORTS 902 TOTAL FATAL OUTCOME REPORTS 5 Report Run Date: 06-Dec-2017, Page 23

25 Four component meningococcal group B vaccine (Bexsero, 4CMenB) Figure A.

26 Figure B. Figure C.

27 13-valent Pneumococcal Conjugate Vaccine (PCV13) Figure D.

28 Figure E.

29 Figure F. Rotavirus Vaccine

30 Figure G.

31 Figure H.

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014 - 16Oct2014 Report Run Date: 20-Oct-2014 Data Lock Date: 16-Oct-2014 19:00:06 Earliest Reaction Date: 28-Oct-2009 MedDRA Version: MedDRA 17.0 Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine : Alle cases

More information

Case Series Drug Analysis Print Name: DTPa IPV HIB

Case Series Drug Analysis Print Name: DTPa IPV HIB Report Run Date: 20-Feb-2014 Data Lock Date: 18-Feb-2014 01:01:22 Earliest Reaction Date: 02-Oct-2002 MedDRA Version: MedDRA 16.1 DTPa IPV HIB: Drug Analysis Print Report Run Date: 20-Feb-2014, Page 1

More information

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015 1 2015-023780 2015-023788 2015-023805 2015-023819 2015-023820 2015-023821 Injection site swelling Transient immobility Abdominal pain Visual acuity reduced Chronic fatigue syndrome Mental disorder Pallor

More information

Suspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine

Suspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine Suspected Adverse Reaction Analysis CERVARIX Human papillomavirus (HPV) vaccine 2 May 2009 This report summarises the adverse reactions suspected to have been caused by Cervarix human papillomavirus (HPV)

More information

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines Adverse events following immunisation (AEFI) with 00/0 seasonal influenza vaccines Netherlands Pharmacovigilance Centre Lareb 8 juli 0 Goudsbloemvallei 7 57 MH s-hertogenbosch www.lareb.nl info@lareb.nl

More information

Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring

Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring ENCePP Plenary meeting Xavier Kurz 8 June 20 An agency of the European Union Contents 1. Safety database at time of authorisation

More information

Database of Adverse Event Notifications - medicines

Database of Adverse Event Notifications - medicines Database of Adverse Event Notifications - medicines You searched for the following 3 medicines between 01/01/2017 01/01/2018: Ferinject 100mg/2mL (Ferric carboxymaltose) Ferinject 500mg/10mL (Ferric carboxymaltose)

More information

Case Series Drug Analysis Print Name: Isotretinoin

Case Series Drug Analysis Print Name: Isotretinoin Report Run Date: 30-Dec-2013 Data Lock Date: 27-Dec-2013 23:09:23 Earliest Reaction Date: 12-Jun-1997 MedDRA Version: MedDRA 16.1 Isotretinoin: No description provided. Report Run Date: 30-Dec-2013, Page

More information

Case Series Drug Analysis Print Name: Gardasil

Case Series Drug Analysis Print Name: Gardasil Report Run Date: 12-Mar-2015 Data Lock Date: 11-Mar-2015 19:00:07 Earliest Reaction Date: 29-Nov-2006 MedDRA Version: MedDRA 17.1 Gardasil: Gardasil Drug Analysis Print Report Run Date: 12-Mar-2015, Page

More information

MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations.

MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic

More information

Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015

Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015 Page 1 of 6 Adverse (s) Date Outcome 2014-019844 04/03/2014 13 Years Prophylaxis GARDASIL 04/12/2013 Nausea 04/12/2013 06/12/2013 Headache 04/12/2013 06/12/2013 Vomiting 04/12/2013 06/12/2013 Asthenia

More information

FEVER. What is fever?

FEVER. What is fever? FEVER What is fever? Fever is defined as a rectal temperature 38 C (100.4 F), and a value >40 C (104 F) is called hyperpyrexia. Body temperature fluctuates in a defined normal range (36.6-37.9 C [97.9-100.2

More information

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Information from Uppsala Monitoring Centre regarding cases in VigiBase

Information from Uppsala Monitoring Centre regarding cases in VigiBase Information from Uppsala Monitoring Centre regarding cases in VigiBase The Danish Health and Medicines Agency (DHMA) requested a consultation with the WHO Collaborating Centre for International Drug Monitoring

More information

MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia.

MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia. ALL REPORT DATES Causality Unclear Excluded Total Death Outcome Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders

More information

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425) IDENTIFYING INFORMATION PATIENT INFORMATION FORM Patient's Name: DOB: Ethnicity/race: Gender: Primary language if other than English: Address: Phone: Home/ Mobile/ Work Email: Occupation: Marital Status:

More information

V F 4 Years N Recovered DT FEVER INJECTION SITE REACTION

V F 4 Years N Recovered DT FEVER INJECTION SITE REACTION * CAVEAT: The vast majority of reports on which this summary is based are submitted by health practitioners. Each report represents the suspicion, opinion or observation of the individual reporter. Cause

More information

Medicine summary - Antipsychotics- chlorpromazine

Medicine summary - Antipsychotics- chlorpromazine 591 21 241 Blood and lymphatic system disorders Anaemia 3 0 0 Aplastic anaemia 3 1 0 Pancytopenia 2 1 1 Thrombocytopenia 6 1 1 Thrombocytosis 1 0 0 Lymphadenopathy 3 1 1 Eosinophilia 5 0 0 Leukocytosis

More information

Case Series Drug Analysis Print Name: Gardasil Product Analysis Print

Case Series Drug Analysis Print Name: Gardasil Product Analysis Print Report Run Date: 14-Aug-2017 Data Lock Date: 11-Aug-2017 19:00:04 Earliest Reaction Date: 17-Nov-2008 MedDRA Version: MedDRA 20.0 Gardasil Product Analysis Print: All UK spontaneous cases concerning Gardasil

More information

Case Series Drug Analysis Print Name: Men C

Case Series Drug Analysis Print Name: Men C Report Run Date: 20-Feb-2014 Data Lock Date: 18-Feb-2014 01:01:22 Earliest Reaction Date: 01-Nov-1999 MedDRA Version: MedDRA 16.1 Men C: Drug Analysis Print Report Run Date: 20-Feb-2014, Page 1 Blood disorders

More information

CENTRAL CARE POLICY SYMPTOMS OF ILLNESS. Policy: Consumers will be observed for symptoms of physical problems, distress, pain, or unusual behaviors.

CENTRAL CARE POLICY SYMPTOMS OF ILLNESS. Policy: Consumers will be observed for symptoms of physical problems, distress, pain, or unusual behaviors. Page 1 of 5 CENTRAL CARE POLICY SYMPTOMS OF ILLNESS SUBJECT: SYMPTOMS OF ILLNESS ANNUAL REVIEW MONTH: June RESPONSIBLE FOR REVIEW: Director of Central Care LAST REVISION DATE: June 2009 Policy: Consumers

More information

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash -

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash - Review of Systems: 0-1 year old Constitution neg Eyes neg GI neg Neurological neg + Activity Change - + Eye Discharge - + Reflux - + Facial Asymmetry - + Appetite Change - + Eye Redness - + Vomiting -

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion

More information

Fever in children aged less than 5 years

Fever in children aged less than 5 years Fever in children aged less than 5 years A fever is defined as a temperature greater than 38 degrees celsius Height and duration of fever do not identify serious illness. However fever in children younger

More information

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: 0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR: Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension

More information

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.)

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.) Date: Patient Name: D.O.B Last First M.I History of Present Illness: What is the reason for your visit? Date symptom started? Please list any treatments you have previously had for current illness. (Physical

More information

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults

More information

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology REVIEWED DATE / INITIALS Safety: Yes No Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: Yes No If YES, please list medication allergies:

More information

RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.

RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1. RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition

U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition CFSAN Adverse Event Reporting System Voluntary and Mandatory Reports on 5-Hour Energy,

More information

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine

More information

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology REVIEWED DATE / INITIALS Safety: Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: If YES, please list medication allergies: Do you have

More information

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1 Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma

More information

MEDICAL ASSESSMENT PART 1 - SOCIAL HISTORY

MEDICAL ASSESSMENT PART 1 - SOCIAL HISTORY Smoking history Alcohol history Never Quit Never Quit PART 2 - MEDICAL HISTORY Date of last colonoscopy? Date of last mammogram? Date of last pap smear? Date of last flu vaccine? Date of last pneumonia

More information

The Limits of Harm Reduction? Neil McKeganey Centre for Substance Use Research West of Scotland Science Park Glasgow Scotland

The Limits of Harm Reduction? Neil McKeganey Centre for Substance Use Research West of Scotland Science Park Glasgow Scotland The Limits of Harm Reduction? Neil McKeganey Centre for Substance Use Research West of Scotland Science Park Glasgow Scotland Principle of Harm Reduction First Do No Harm Hippocratic Oath I will use treatment

More information

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber.

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber. Know Your Medicines Duloxetine The purpose of this leaflet is to give you some general information on duloxetine, and is intended as a guide only. This should be read in conjunction with the official patient

More information

NeisVac-C Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate)

NeisVac-C Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate) NeisVac-C Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about

More information

New Patient Sleep Intake

New Patient Sleep Intake New Patient Sleep Intake Name: Date of Birth: Primary Care Physician: Date of Visit: Referring Physician and/or Other Physicians: Retail Pharmacy: Mail Order Pharmacy: Address: Mail Order Phone #: Phone

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes.

PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes. Name: DOB: PERSONAL MEDICAL AND FAMILY HISTORY Please check applicable boxes. TOBACCO USE: Quit Date Cigarettes Packs/Day Number of years smoked Pipe/Cigar Smokeless Tobacco Electronic or E-cigarette Secondhand

More information

Questionnaire for Lipedema Patients

Questionnaire for Lipedema Patients Questionnaire for Lipedema Patients Name Date of diagnosis Date Name of physician making diagnosis Do you also have lymphedema? What areas of the body are affected? Outside of thighs Inner thighs Knees

More information

WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS

WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS Prior to your office visit, we request that you complete this questionnaire. It asks questions not only about your sleeping habits and behavior

More information

UK Suspected Adverse Reaction Analysis

UK Suspected Adverse Reaction Analysis UK Suspected Adverse Reaction Analysis Swine Flu (H1N1) Vaccines Celvapan and Pandemrix 31 December 2009 This report provides an overview of all UK reports of suspected adverse reactions to the new swine

More information

CONSULTATION ADMITTANCE FORM

CONSULTATION ADMITTANCE FORM CONSULTATION ADMITTANCE FORM Last Name: First Name: Address: City Postal Code: Home Phone: Work Phone: Age: Birth date (dd/mm/yr): Sex: M / F Height Weight Occupation: Alberta Health Care #: PLEASE CHECK

More information

Headache Follow-up Visit Form

Headache Follow-up Visit Form !1 Headache Follow-up Visit Form We will be unable to see you unless this form is completely filled out. We appreciate your thoroughness. Name DOB Age Today s Date Referring doctor: Primary doctor: Neurologist:

More information

Broward Oncology Associates, P.A. PATIENT INFORMATION

Broward Oncology Associates, P.A. PATIENT INFORMATION NAME: BIRTHDATE: AGE: LOCAL ADDRESS (Street city state zip): HOME TELEPHONE# CELL # SOCIAL SECURITY #: - - SEX MARITAL STATUS WHAT IS YOUR HT? WHAT IS YOUR WT? EMPLOYER WORK# SPOUSE'S NAME SPOUSE'S EMPLOYER

More information

History Taking 3rd year Lecture. Thembi Katangwe 1st March 2011

History Taking 3rd year Lecture. Thembi Katangwe 1st March 2011 History Taking 3rd year Lecture Thembi Katangwe 1st March 2011 Objectives To understand that the parent / guardian is the historian Build a rapport with parent/guardian as well as older children To understand

More information

New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care

New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care Page 1 of 7 Patient Demographics First Name* Last Name* Date Of Birth* Home Phone* Mobile Phone Phone Gender* Email Preferred Communication Street Address 1* Street Addresss 2 Zip* City* State* Emergency

More information

Medicine summary - Antipsychotics- haloperidol

Medicine summary - Antipsychotics- haloperidol 748 22 330 Blood and lymphatic system disorders Anaemia 2 0 0 Bone marrow failure 1 0 0 Pancytopenia 4 0 1 Haemolytic anaemia 1 0 0 Thrombocytopenia 2 0 0 Lymphadenopathy 1 0 0 Splenomegaly 2 0 0 Eosinophilia

More information

Northeast Ohio Urogynecology Patient History Intake Form. Last Name First Name Age. Date of Birth Race Referring Physician.

Northeast Ohio Urogynecology Patient History Intake Form. Last Name First Name Age. Date of Birth Race Referring Physician. Northeast Ohio Urogynecology Patient History Intake Form Last Name _First Name Age_ Date of Birth Race Referring Physician Reason for Visit: _ Allergies: Preferred Lab (circle): QUEST LABCARE PLUS LABCORP

More information

TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM

TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM PATIENT NAME: DATE OF BIRTH: TVA Physician being seen: Date of Visit: PAST MEDICAL HISTORY HEART PROBLEMS NEUROLOGICAL Congestive Heart Failure

More information

2. Have your symptoms affected your ability to carry out your daily activities? YES NO

2. Have your symptoms affected your ability to carry out your daily activities? YES NO QUESTIONNAIRE Page 1 of 5 Date: Referring MD (Name, Address, Phone Number): Primary Care Physician (Name and Address, Phone Number): Reason for visit: 1. How long have you had symptoms? Describe your symptoms?

More information

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride Package leaflet: Information for the patient Cetirizin Sandoz 10 mg film-coated tablets cetirizine dihydrochloride [For medicine available only on prescription:] Read all of this leaflet carefully before

More information

Neonatal and infant health. What to look out for in babies up to 6 months old. Anoo Jain Neonatal Consultant

Neonatal and infant health. What to look out for in babies up to 6 months old. Anoo Jain Neonatal Consultant Neonatal and infant health What to look out for in babies up to 6 months old Anoo Jain Neonatal Consultant CONTEXT Obstetrics Local & Regional Maternal Medicine Fetal Medicine NICU Genetics/ENT/Gynae Content

More information

PLEASE COMPLETE ALL SECTIONS OF THIS FORM

PLEASE COMPLETE ALL SECTIONS OF THIS FORM PLEASE COMPLETE ALL SECTIONS OF THIS FORM Patient Name: Date of Birth: Referring Doctor? (Name, telephone number and address) Chief Complaint: Why have you come here? How did it start? What are the symptoms?

More information

BOOSTRIX. Combined diphtheria, tetanus, acellular pertussis vaccine

BOOSTRIX. Combined diphtheria, tetanus, acellular pertussis vaccine BOOSTRIX Combined diphtheria, tetanus, acellular pertussis vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml) contains: Diphtheria toxoid 1 Tetanus toxoid 1 Bordetella pertussis antigens

More information

Sleep Center. Have you had a previous sleep study? Yes No If so, when and where? Name of facility Address

Sleep Center. Have you had a previous sleep study? Yes No If so, when and where? Name of facility Address Patient Label For office use only Appt date: Clinician: Sleep Center Main Campus Highlands Ranch Location 1400 Jackson Street 8671 S. Quebec St., Ste 120 Denver, CO 80206 Highlands Ranch, CO 80130 Leading

More information

Anaphylaxis: treatment in the community

Anaphylaxis: treatment in the community : treatment in the community Item Type Guideline Authors Health Service Executive Citation Health Service Executive. : treatment in the community. Dublin: Health Service Executive;. 5p. Publisher Health

More information

Management of an immediate adverse event following immunisation

Management of an immediate adverse event following immunisation Management of an immediate adverse event following immunisation The vaccinated person should remain under observation for a short interval to ensure that they do not experience an immediate adverse event.

More information

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Package leaflet: Information for the user Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Anaphylaxis: Treatment in the Community

Anaphylaxis: Treatment in the Community : Treatment in the Community is likely if a patient who, within minutes of exposure to a trigger (allergen), develops a sudden illness with rapidly progressing skin changes and life-threatening airway

More information

Patient Intake Form for Allegany Ear, Nose, & Throat

Patient Intake Form for Allegany Ear, Nose, & Throat Patient Intake Form for Allegany Ear, se, & Throat Patient Name: What brings you to the office today? Who is your primary care doctor? Please list your current medications: Are you allergic to any medications?

More information

725 Jesse Jewell Pkwy, Suite 390 Gainesville, GA (770) (770) (facsimile)

725 Jesse Jewell Pkwy, Suite 390 Gainesville, GA (770) (770) (facsimile) Charles Nash, III, M.D., F.A.C.P. Richard J. LoCicero, M.D. Anup K. Lahiry, M.D. Timothy M. Carey, M.D. Andrew Johnson, M.D. 725 Jesse Jewell Pkwy, Suite 390 Gainesville, GA 30501 (770) 297-5700 (770)

More information

Faculty of Clinical Forensic Medicine Committee 1/2018

Faculty of Clinical Forensic Medicine Committee 1/2018 Guideline Subject: Clinical Forensic Assessment and Management of Non-Fatal Strangulation Approval Date: January 2018 Review Date: January 2021 Review By: Number: Faculty of Clinical Forensic Medicine

More information

MARYWOOD UNIVERSITY PHYSICIAN ASSISTANT PROGRAM HISTORY, PHYSICAL, ASSESSMENT AND PLAN

MARYWOOD UNIVERSITY PHYSICIAN ASSISTANT PROGRAM HISTORY, PHYSICAL, ASSESSMENT AND PLAN MARYWOOD UNIVERSITY PHYSICIAN ASSISTANT PROGRAM HISTORY, PHYSICAL, ASSESSMENT AND PLAN PA: PRECEPTOR: MARYWOOD STAFF: PATIENT ID: AGE: SEX: DATE: Chief Complaint: History of Present Illness: 1 Medications:

More information

Urticaria Moderate Allergic Reaction Mild signs/symptoms with any of following: Dyspnea, possibly with wheezes Angioneurotic edema Systemic, not local

Urticaria Moderate Allergic Reaction Mild signs/symptoms with any of following: Dyspnea, possibly with wheezes Angioneurotic edema Systemic, not local Allergic Reactions & Anaphylaxis Incidence In USA - 400 to 800 deaths/year Parenterally administered penicillin accounts for 100 to 500 deaths per year Hymenoptera stings account for 40 to 100 deaths per

More information

Package Leaflet: Information for the user. Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed)

Package Leaflet: Information for the user. Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed) Package Leaflet: Information for the user Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed) Read all of this leaflet carefully before you or your

More information

What do you believe is causing your most important health concern?

What do you believe is causing your most important health concern? Intake form Name Today s Date Date of Birth Address City Phone Postal Code Email Primary Health Care Provider Emergency Contact Phone Note: By providing your email address you are giving us consent to

More information

Emotional Relationships Social Life Sexually Recreation

Emotional Relationships Social Life Sexually Recreation Name Date Address City State Zip Married Single Partner Divorced Widowed Date of Birth SS# Email Work Phone Home Phone Cell Phone Occupation Referred by Emergency Contact Family Physician Contact May we

More information

LECOM Health Ophthalmology

LECOM Health Ophthalmology Patient Name: Date of Birth: New Patient Questionnaire Your answers will be used by your healthcare provider get an accurate history of your medical conditions and ocular concerns. If you are uncomfortable

More information

Syncope and Seizure Questionnaire

Syncope and Seizure Questionnaire Syncope and Seizure Questionnaire World College of Neurology 2/79 Wheatley Drive Bull Creek WA 6149 T 08 93320488 F 08 93329988 Copyright 2011. All rights reserved. Patient Name: MAIN PROBLEM I am here

More information

PRODUCT MONOGRAPH. Pr MYOZYME. alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial. Enzyme Replacement Therapy

PRODUCT MONOGRAPH. Pr MYOZYME. alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial. Enzyme Replacement Therapy PRODUCT MONOGRAPH Pr MYOZYME alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial Enzyme Replacement Therapy Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.

More information

IMOJEV Japanese encephalitis vaccine (live, attenuated)

IMOJEV Japanese encephalitis vaccine (live, attenuated) IMOJEV Japanese encephalitis vaccine (live, attenuated) Consumer Medicine Information What is in this leaflet Read all of this leaflet carefully before you or your child is vaccinated. Keep this leaflet.

More information

UK Suspected Adverse Drug Reaction (ADR) Analysis

UK Suspected Adverse Drug Reaction (ADR) Analysis UK Suspected Adverse Drug Reaction (ADR) Analysis Influenza antivirals - oseltamivir (Tamiflu) and zanamivir (Relenza) 26 th November 2009 This report summarises all UK reports of suspected adverse drug

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR: Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications

More information

Amarillo Surgical Group Doctor: Date:

Amarillo Surgical Group Doctor: Date: Office Visit Information (General Surgery) Amarillo Surgical Group Doctor: Date: Patient s Information Name: Last First Middle Social Security #: Date of Birth: Age Gender: [ Male / Female ] Marital Status:

More information

Elements for a public summary

Elements for a public summary VI.2 Elements for a public summary Part VI.2 Elements for a public summary is applicable for all products that are covered by this RMP, except from the important potential risk of Medication error with

More information

Medical History Form

Medical History Form General: Medical History Form 1. Chief Complaint: What are the main health concerns you wish to address? 2. Current and Past Treatment: Have you received treatment for these problems? Yes No, if yes, which:

More information

Essential Wellness Of Illinois, LLC Health History Questionnaire Christine A. Renz L.Ac., Dipl OM, MSTOM

Essential Wellness Of Illinois, LLC Health History Questionnaire Christine A. Renz L.Ac., Dipl OM, MSTOM Name Date Address City State Zip Home Phone Cell Fax Email Emergency Contact Emergency Number Date of Birth Age Sex Height Weight Lbs Marital Status Occupation Who referred you to this office? Name of

More information

BCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine.

BCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine. BCHOOSE TO VACCINATED Vaccinate against meningococcal disease caused by Neisseria meningitidis group B strains (MenB) with BEXSERO BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed)

More information

New Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests:

New Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests: New Patient History Name: DOB: Sex: Date: Chief Complaint: 1. Give a brief description of the problem you are seeking treatment for today: 2. Have you been evaluated for this problem or had any tests for

More information

NORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C.

NORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C. NORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C. Past Medical History AIDS/HIV disease Anemia Asthma Bronchitis Cancer Date of last Chest X-ray Diabetes Mellitus, Type I Diabetes Mellitus,

More information

Name: [Type text] Date of Birth: ENDOCRINOLOGY HEALTH HISTORY. What is the reason for your visit?

Name: [Type text] Date of Birth: ENDOCRINOLOGY HEALTH HISTORY. What is the reason for your visit? ENDOCRINOLOGY HEALTH HISTORY What is the reason for your visit? MEDICATIONS List current prescription and over-the-counter medications. Also list current vitamin, herbal, and nutritional supplements: MEDICATION/SUPPLEMENT

More information

Patient Intake Form. Name: Date of Birth: Social Security No.: Address: City: State: Zip:

Patient Intake Form. Name: Date of Birth: Social Security No.: Address: City: State: Zip: Patient Intake Form Name: Date of Birth: Social Security No.: Address: City: State: Zip: Phone (circle 1) home / cell / work: Marital Status: Single / Married / Divorced / Widowed Work Status: Employed

More information

Medical History Form

Medical History Form Medical History Form NAME DOB / / TODAY S DATE MEDICAL HISTORY What medical Conditions do you have? Select all that apply, or write in if not listed: Diabetes High Blood Pressure Thyroid Disorder Heart

More information

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including:

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including: Medication Guide VENLAFAXINE XR (venlafaxine hydrochloride) (Extended-Release Capsules) Read the Medication Guide that comes with venlafaxine hydrochloride extended-release before you start taking it and

More information

NORVASC 5 mg and 10 mg tablets

NORVASC 5 mg and 10 mg tablets PACKAGE LEAFLET: INFORMATION FOR THE USER NORVASC 5 mg and 10 mg tablets AMLODIPINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which

More information

Paediatric ENT problems

Paediatric ENT problems Paediatric ENT problems Ears Otitis media Otitis media with effusion FBs Otitis externa Ruptured TM Nose FBs Allergic rhinitis Septal perforation expistaxis Throat FB Croup Stidor Tonsillitis Paediatric

More information

DIVISION OF CARDIOLOGY

DIVISION OF CARDIOLOGY Name: Date of Birth: / / Home Phone #: Cell Phone #: Work Phone #: Fax #: Address: City: State: Zip: Primary Care Physician: Office Address: Work #: Fax #: Referring Physician (if different): Office Address:

More information

06/09/2005 Medical history and intake form

06/09/2005 Medical history and intake form Medical history and intake form Please complete this form as accurately as possible - it helps to provide you with the best possible treatment. Address including postcode Contact numbers Home/work/mobile

More information

DEEP BRAIN STIMULATION SURGICAL CANDIDACY EVALUATION FORM

DEEP BRAIN STIMULATION SURGICAL CANDIDACY EVALUATION FORM Name: MR#: Date: DEEP BRAIN STIMULATION SURGICAL CANDIDACY EVALUATION FORM Referring Physician s Name: Primary Care Provider s Name: 1. What was/were your first movement disorder symptoms? What did you

More information

The Food Intolerance Institute of Australia

The Food Intolerance Institute of Australia The Intolerance Institute of Australia The Symptoms Matrix The Symptoms Matrix allows you to narrow the possibilities of your food rather than diagnose it. To get an accurate identification of your food

More information

VACCINE-RELATED ALLERGIC REACTIONS

VACCINE-RELATED ALLERGIC REACTIONS VACCINE-RELATED ALLERGIC REACTIONS Management of Anaphylaxis IERHA Immunization Program September 2016 VACCINE-RELATED ADVERSE EVENTS Local reactions pain, edema, erythema Systemic reactions fever, lymphadenopathy

More information

EVALUATION OF A SICK CHILD WITH FEVER

EVALUATION OF A SICK CHILD WITH FEVER EVALUATION OF A SICK CHILD WITH FEVER Learning objectives At the conclusion of this learning activity, participants should be able to; Discuss the different etiologies of acute illness in a child Identify

More information

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS

Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Only valid for adult patients Azathioprine must be at a dose of at least

More information

Supplemental Information

Supplemental Information Supplemental Information SUPPLEMENTAL TABLE 5 Comorbidities and AEs by Patient ID: Cycle 1 5 BoNT-A; Cycle 2 5 2 Sessions BoNT-A 5 Gastrostomy, swallowing problems, drooling, recurrent pain, spasticity

More information

Karl McManus Foundation Representing the Australian Lyme Disease Community Symptoms Monitoring Chart

Karl McManus Foundation Representing the Australian Lyme Disease Community Symptoms Monitoring Chart Name Diagnosis Date Pathogens Present Date GENERAL Fever Chills Night sweats Fatigue Poor Stamina Weight Loss/Gain Gernalised Pain Migratory Pain Shooting Pain Daytime Napping Menstrual Irregularity Milk

More information

PLEASE LET US KNOW YOUR REASON FOR TODAY S VISIT : CURRENT MEDICATIONS (WITH DOSAGE) PLEASE INCLUDE VITAMINS AND HERBAL MEDICATIONS:

PLEASE LET US KNOW YOUR REASON FOR TODAY S VISIT : CURRENT MEDICATIONS (WITH DOSAGE) PLEASE INCLUDE VITAMINS AND HERBAL MEDICATIONS: 1 NAME: DATE OF BIRTH PLEASE LET US KNOW YOUR REASON FOR TODAY S VISIT : CURRENT MEDICATIONS (WITH DOSAGE) PLEASE INCLUDE VITAMINS AND HERBAL MEDICATIONS: PAST MEDICAL HISTORY (YOUR MEDICAL HISTORY) :

More information

PULMONARY CARE OF CENTRAL FLORIDA, P.A. Date: / /

PULMONARY CARE OF CENTRAL FLORIDA, P.A. Date: / / PULMONARY CARE OF CENTRAL FLORIDA, P.A. Date: / / Patient Name Age DOB: / / Family Physician Referring Physician Telephone Number Telephone Number Pharmacy: Phone: Fax: MEDICAL HISTORY 1. What is your

More information